Printer Friendly

VIP: "very important peptide' in AIDS?

VIP: 'Very important peptide' in AIDS?

Scientists at the National Institute of Mental Health (NIMH) in Bethesda, Md., recently found a small protein that blocks the AIDS-causing virus, known as human immunodeficiency virus (HIV), at receptor sites on critical T4 immune cells (SN: 12/20&27/86, p.388). The protein, dubbed Peptide T, was isolated from the HIV envelope protein and is being tested on Swedish and U.S. AIDs patients (SN: 6/13/87, p.376).

At a seminar last week, the NIMH investigators described evidence suggesting that Peptide T may protect brain and immune cells by mimicking a naturally occurring peptide -- vasoactive intestinal peptide (VIP). The two peptides contain a similar "core" sequence of five amino acids, says one of the researchers, Candace B. Pert, and both appear to attach to T4 receptors in the brain.

In experiments directed by Douglas E. Brenneman, VIP and Peptide T similarly protected mouse neurons in laboratory cultures from dying after exposure to low concentrations of the HIV envelope protein. On their own, significant numbers of the neurons perished at the same concentrations. Three other peptides that act on the brain and are related to VIP offered no protection against the cell destruction inflicted by the AIDS virus, says Brenneman.

Preliminary work suggests that VIP acts at three T4 receptor subtypes, says NIMH's Joanna M. Hill. Peptide T may act at only one of those subtypes, she notes. Furthermore, there are numerous T4 receptors in the cerebellum and basal ganglia, brain structures implicated in the dementia and muscular disorders that often accompany AIDS.

"My working theory, which is still largely speculative," says Hill, "is that much of AIDS dementia and motor dysfunction is caused by HIV envelope protein binding to T4 receptors in the brain and preventing normal VIP functions."

A preliminary clinical trial of five patients in the early stages of AIDS injected with Peptide T for 30 days resulted in all the subjects reporting more energy, says Peter Bridge of NIMH. Skin diseases, such as psoriasis, subsided in three of the patients, as did persistent, watery diarrhea in one subject. But the ability to copy a complex geometric figure from memory was severely impaired in four of the patients, observes Bridge.

Peptide T's usefulness in treating AIDS, and particularly in reversing the loss of concentration and memory, remains unclear, he says. A trial of six patients treated with the protein and six given a placebo is now underway at the University of Southern California in Los Angeles. Subjects have been difficult to recruit, he adds, often because they are unwilling to give up other unconventional AIDS treatments during Peptide T trials.
COPYRIGHT 1988 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1988, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:peptide T
Publication:Science News
Date:Feb 20, 1988
Previous Article:UV radiation decreasing over U.S.?
Next Article:Facelift for newborn imitation.

Related Articles
AIDS studies suggest new directions, therapies.
Heart peptide goes to the head.
Peptide T: future AIDS treatment?
HIV: more tricks up its sleeve.
AIDS: building a better inhibitor.
AIDS dementia: neurons nixed by virus?
Where's the beef? In a meaty peptide.
Material peptide: a piece of protein yeast becomes a building block for scientists.
Blocking multiple sclerosis in a mouse model.
For possible AIDS drug, smaller is better.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters